ITEMS OF INTEREST TO THE IMAGING RESEARCH COMMUNITY:
- NAME CHANGE: The Diagnostic Imaging Program has changed its name to the Cancer Imaging Program so that the name more accurately reflects the program's aims and portfolio. You can expect to see both names for a little while.
- INTERDISCIPLINARY RESEARCH TEAMS FOR MOLECULAR TARGET ASSESSMENT (NCI) (RFA-CA-00-001)
Letter of Intent Receipt Date: February 1, 2000; Application Receipt Date: March 15, 2000
The purpose of this initiative is to discover, develop and validate the research tools that will make mechanism assessment in clinical trials and preclinical cancer models a reality. Preclinical and clinical research with novel agents for cancer treatment and prevention requires usable tools to determine that the agent has affected the intended molecular target. Applicants must describe their resources and plans for correlative imaging studies.
- EARLY THERAPEUTICS DEVELOPMENT WITH PHASE 2 EMPHASIS (NCI) (RFP N01-CM-07003-74)
DUE: March 9, 2000
The Cancer Therapy Evaluation Program (CTEP), of the Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI) is seeking organizations or consortia with the capabilities and facilities to provide a resource for the conduct of Phase 2 and early clinical trials of NCI-sponsored agents, to evaluate biologic effects of these agents on their molecular targets, to evaluate other relevant biologic effects and to determine clinically relevant outcomes/correlates. Applications that include correlative imaging studies are encouraged.
- BIOENGINEERING RESEARCH PARTNERSHIPS REVISIONS TO PAS-00-006 (NOTICE: OD-00-003)
Letter of Intent Receipt Dates: December 15, 1999 and June 30, 2000
Application Receipt Dates: January 7, 2000 and August 10, 2000
The Program Announcement (PA), PAS-00-006, published in the NIH Guide on October 15, 1999 has been revised. The major revision is that the pilot project for electronic submission of BRP applications has been postponed. All applications for the January 7, 2000 receipt date must be submitted using the PHS 398 (rev. 4/98) application form in the usual paper format. The revised PA has been republished in the NIH Guide for Grants and Contracts and is available at
- NOVEL TECHNOLOGIES FOR NONINVASIVE DIAGNOSIS, TREATMENT OF CANCER - NIH (BAA N01-CO-07013-32)
DUE: March 3, 2000
The Unconventional Innovations Program (UIP) of the National Cancer Institute (NCI) is seeking revolutionary technologies for cancer research. The UIP is soliciting proposals for the development of multifunctional technology platforms to support minimally intrusive approaches that integrate: a) sensing of the fundamental signatures of precancers, or early, metastatic, or recurring cancers in the living body, b) transmission of signature information to an external monitor, c) controlled, specific, treatment, d) monitoring of the effects of treatment. The UIP particularly seeks technology platforms that integrate novel approaches to signature recognition, signal generation, signal amplification, signal transmission, intervention delivery, intervention feedback, and data interpretation.
- BECON MEETING: Nanoscience and Nanotechnology: Shaping Biomedical Research
The National Institute's of Health (NIH) Bioengineering Consortium (BECON) is organizing a symposium on nanotechnology during June 25-26, 2000, at the Natcher Conference Center on the NIH Main Campus in Bethesda, Maryland. The essence of nanotechnology is the use of unique properties, phenomena, and processes of materials and systems that occur at the molecular (1 - 100 nanometer) scale. Nanotechnology is emerging as a field that has the potential to revolutionize health care and medicine, biotechnology, manufacturing, energy, and information processing.
- BECON 1999 Symposium Report
The final version of the BECON Symposium Report is on the web:
ADOBE VERSION at: http://grants.nih.gov/grants/becon/report_19990625.pdf
- APPLICABILITY OF MODULAR GRANT APPLICATION AND AWARD PROCEDURES TO NATIONAL CANCER INSTITUTE PROGRAM ANNOUNCEMENTS
The National Cancer (NCI) wishes to give notice that beginning with the June 1, 1999 receipt date, "Modular Grant Application and Award" procedures will apply to all competing individual research project grant (R01), and exploratory/developmental grant (R21) applications requesting up to $250,000 direct cost per year, submitted in response to NCI program announcements. at URL: http://grants.nih.gov/grants/funding/modular/modular.htm
- CANCER PREVENTION RESEARCH SMALL GRANT PROGRAM (PAR-00-025) (NCI)
Application Receipt Date: March 20, July 20, November 20
This PA replaces PAR-95-091, which was published in the NIH Guide, Volume 24, Number 33, September 22, 1995.
The Division of Cancer Prevention of the National Cancer Institute (NCI) invites applications that address developmental research in chemoprevention agent development, biomarkers, early detection, and nutrition science. The Small Grants Program is designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of research expertise in cancer prevention research. It is anticipated that these Small Grant Programs may lead to the submission of subsequent Individual Research Project Grants (R01).
URL : http://grants.nih.gov/grants/guide/pa-files/PAR-00-025.html
- NCRR SHARED INSTRUMENTATION GRANT (PAR-00-031)
NCRR SHARED INSTRUMENTATION GRANT
Application Receipt Date: March 17, 2000
The National Center for Research Resources (NCRR) is continuing its competitive Shared Instrumentation Grant (SIG) Program initiated in Fiscal Year 1982. The objective of the program is to make available to institutions expensive research instruments that can only be justified on a shared-use basis and for which meritorious research projects are described. The SIG Program provides a cost-effective mechanism for groups of NIH-supported investigators to obtain commercially-available, technologically sophisticated equipment costing more than $100,000.
- OXYGEN SENSING DURING INTERMITTENT HYPOXIA (NHLBI) (RFA-HL-00-004)
Letter of Intent Receipt Date: January 24, 2000; Application Receipt Date: February 23, 2000
The purpose of this initiative is to improve our understanding of how intermittent hypoxia contributes to the pathophysiology of cardiopulmonary, vascular, hematological, and sleep disorders. Specific objectives are to determine the basic molecular and genomic mechanisms involved in cellular responses to brief intermittent hypoxic episodes including mechanisms responsible for the detection and signaling of oxygen level changes, and the mechanisms that mediate adaptive changes in metabolism, oxygen sensing, and gene expression.
- DEEP INFECTIONS OF TOTAL JOINT REPLACEMENTS (NIAMS, NICHD) (PA-00-014)
Total joint replacement has been shown to be a highly effective treatment for end-stage arthritis of the major weight-bearing joints. Despite this success, complications persist, including dislocation, deep infection, aseptic loosening and osteolysis. Although relatively uncommon, deep infections in a total joint replacement are potentially catastrophic events for patients and for society. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Institute of Child Health and Human Development (NICHD) seek to stimulate the receipt of a broad range of basic science and clinical studies to better understand the pathophysiology, diagnosis and treatment of deep infections around total joint replacement implants.
URL : http://grants.nih.gov/grants/guide/pa-files/PA-00-014.html
OTHER GOVERNMENT AGENCIES
- GRANT APPLICATIONS TO THE DEPARTMENT OF ENERGY'S SBIR AND STTR PROGRAMS
Applications due: February 29, 2000
Small Business Innovation Research (SBIR) grants and Small Business Technology Transfer (STTR) grants were designed by the DOE to assist small businesses (venture capital companies included) to develop the scientific data needed to obtain larger grants or to effect successful technology transfer to larger companies. A university researcher or private practice physician can gain access to these grants by establishing a link with a small business concern or venture capital group. Phase 1 SBIR grants are limited to $100,000 for one year, but phase 2 grant awards provide $750,000 over 3 years, with an option for a 20% overrun (i.e. nearly $ 1 million total award!). Grant applications are sought in 40 technical areas, including nuclear medicine and bioengineering, as described in the WEB announcement at
- ADVANCED NUCLEAR MEDICINE INITIATIVE- DOE
The Office of Isotope Programs, Office of Nuclear Energy, Science and Technology (NE) solicits responses for research and development programs for new and innovative uses of isotopes, including alpha-emitting isotopes in the diagnosis and therapy of cancer, HIV and other infectious diseases or other innovative medical applications. The diagnosis and therapy of many diseases with the use of isotopes will be the subject of a high risk/high impact research program the Department calls the Advanced Nuclear Medicine Initiative (ANMI). The Department wishes to encourage research in these areas by providing resources for the required research. The DOE points of contact are John Pantaleo, Program Manager at 301-903-2525 and Richard G. Lewis, Contracting Officer at 202-426-0066. Complete details, instructions on how to apply, opening and closing dates and the forms may be obtained from the DOE NE home page on the internet at:
- DEPARTMENT OF ENERGY: ANNUAL NOTICE OF CONTINUATION OF AVAILABILITY OF GRANTS AND COOPERATIVE AGREEMENTS.
The Office of Science of the Department of Energy hereby announces its continuing interest in receiving grant applications for support of work in the following program areas: Basic Energy Sciences, High Energy Physics, Nuclear Physics, Computational and Technology Research, Fusion Energy Sciences, and Biological and Environmental Research. Biological and Environmental Research Program: Medical Applications and Measurement Science: The research is designed to develop beneficial applications of nuclear and other energy-related technologies for medical diagnosis and treatment. The research is directed at discovering new applications of radiotracer agents for medical research as well as for clinical diagnosis and therapy. A major emphasis is placed on application of the latest concepts and developments in genomics, structural biology, computational biology, and instrumentation. Much of the research seeks breakthroughs in noninvasive imaging technologies such as positron emission tomography. The measurement science activities focus on research in the basic science of chemistry, physics and engineering as applied to bioengineering. Program Contact: (301) 903-3213.
- 2000-2001 FELLOWSHIP PROGRAM IN WOMEN'S HEALTH (Society of Nuclear Medicine)
The Society of Nuclear Medicine's Committee on Awards, through the generous support of DuPont Pharmaceuticals Company, is offering one grant for $30,000 available for July 2000 for research in women's health. Application forms may be downloaded. The deadline for receipt of applications is February 1, 2000.
The Diagnostic Imaging Program at NCI has created this e-mail distribution list to notify interested people about funding opportunities and other issues related to imaging research. Its primary purpose is to call your attention to important, relevant information on NIH Web pages, or in the NIH Guide. Occasionally it may be used to clarify areas of confusion, or disseminate answers to frequently asked questions.
If you wish to remain on the list, no action is necessary.
If you wish to be added to the list (or removed from it), please contact Johnnie Smith by return e-mail (email@example.com).
The staff of the Diagnostic Imaging Program places a high priority on communicating with and facilitating the work of researchers in the imaging community. We look forward to working with you.
Diagnostic Imaging Program Division of Cancer Treatment and Diagnosis, NCI Executive Plaza North, Room 800 6130 Executive Boulevard Rockville, MD 20892-7440 Tel: 301 496 9531 Fax: 301 480 5785